Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn more about how treatment with vitamin D can affect iron
metabolism and blood levels of hepcidin (hormone controlling iron levels) in people with
chronic kidney disease (CKD).
Iron is an essential mineral which is a major component of proteins that carry oxygen in the
blood. Problems with iron metabolism can lead to low blood levels (anemia), which can
commonly happen in people with CKD.
New research over the last decade has uncovered a new hormone called 'hepcidin', which is
made in the liver and released into the blood. Hepcidin controls how much iron is in the
blood by preventing the absorption of iron from food. Blood levels of hepcidin C are found to
be high in people with CKD, and a recent small study in people with normal kidney function
showed that treatment with vitamin D decreased hepcidin levels.
In this study, investigators would like to examine the effects of vitamin D (Ergocalciferol)
on iron metabolism and blood levels of hepcidin in individuals with CKD.